B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-03-24

AUTHORS

Cynthia Shepherd, Igor Puzanov, Jeffrey A. Sosman

ABSTRACT

Immunotherapy and chemotherapy benefit few patients with metastatic melanoma, and even fewer experience durable survival benefit. These poor results come from treating melanoma as a single homogeneous disease. Recently, it has been shown that targeting activated tyrosine kinases (oncogenes) can mediate striking clinical benefits in several cancers. In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase was described as present in over 50% of melanomas. The mutation appeared to confer a dependency by the melanoma cancer cell on its activation of the MAP kinase pathway. The frequency and specificity of this mutation (95% at V600E of BRAF) suggests that it may be a potential target for therapy, and recent results with one inhibitor, PLX4032/RG7204, bare this out. This review updates the status of BRAF inhibitors in melanoma and what may be on the horizon. More... »

PAGES

146-152

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11912-010-0095-2

DOI

http://dx.doi.org/10.1007/s11912-010-0095-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003251632

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20425073


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins B-raf", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shepherd", 
        "givenName": "Cynthia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puzanov", 
        "givenName": "Igor", 
        "id": "sg:person.0640153517.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sosman", 
        "givenName": "Jeffrey A.", 
        "id": "sg:person.07375610737.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07375610737.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1206461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049450168", 
          "https://doi.org/10.1038/sj.onc.1206461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005853584", 
          "https://doi.org/10.1038/sj.bjc.6603291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/459336a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015003021", 
          "https://doi.org/10.1038/459336a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature07586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018711414", 
          "https://doi.org/10.1038/nature07586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03890", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003324113", 
          "https://doi.org/10.1038/nature03890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng1054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035969538", 
          "https://doi.org/10.1038/ng1054"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11912-009-0054-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005461340", 
          "https://doi.org/10.1007/s11912-009-0054-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2008.362", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024888641", 
          "https://doi.org/10.1038/onc.2008.362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200767080-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012080940", 
          "https://doi.org/10.2165/00003495-200767080-00003"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-03-24", 
    "datePublishedReg": "2010-03-24", 
    "description": "Immunotherapy and chemotherapy benefit few patients with metastatic melanoma, and even fewer experience durable survival benefit. These poor results come from treating melanoma as a single homogeneous disease. Recently, it has been shown that targeting activated tyrosine kinases (oncogenes) can mediate striking clinical benefits in several cancers. In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase was described as present in over 50% of melanomas. The mutation appeared to confer a dependency by the melanoma cancer cell on its activation of the MAP kinase pathway. The frequency and specificity of this mutation (95% at V600E of BRAF) suggests that it may be a potential target for therapy, and recent results with one inhibitor, PLX4032/RG7204, bare this out. This review updates the status of BRAF inhibitors in melanoma and what may be on the horizon.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11912-010-0095-2", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2420926", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1021174", 
        "issn": [
          "1523-3790", 
          "1534-6269"
        ], 
        "name": "Current Oncology Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "durable survival benefit", 
      "survival benefit", 
      "clinical benefit", 
      "metastatic melanoma", 
      "malignant melanoma", 
      "BRAF inhibitors", 
      "BRAF serine/threonine kinase", 
      "homogeneous disease", 
      "melanoma cancer cells", 
      "melanoma", 
      "cancer cells", 
      "potential target", 
      "MAP kinase pathway", 
      "poor results", 
      "therapy", 
      "kinase pathway", 
      "evolving role", 
      "tyrosine kinase", 
      "serine/threonine kinase", 
      "inhibitors", 
      "mutations", 
      "immunotherapy", 
      "chemotherapy", 
      "patients", 
      "threonine kinase", 
      "cancer", 
      "disease", 
      "kinase", 
      "amino acids", 
      "activation", 
      "benefits", 
      "status", 
      "cells", 
      "review", 
      "pathway", 
      "specificity", 
      "target", 
      "role", 
      "acid", 
      "results", 
      "frequency", 
      "recent results", 
      "dependency", 
      "horizon"
    ], 
    "name": "B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma", 
    "pagination": "146-152", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003251632"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11912-010-0095-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20425073"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11912-010-0095-2", 
      "https://app.dimensions.ai/details/publication/pub.1003251632"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_503.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11912-010-0095-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-010-0095-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-010-0095-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-010-0095-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-010-0095-2'


 

This table displays all metadata directly associated to this object as RDF triples.

176 TRIPLES      21 PREDICATES      83 URIs      65 LITERALS      11 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11912-010-0095-2 schema:about N52d8eb9040b3474bbefaa127a7468c0f
2 N7d5febe9d4534938ac6118b1f50cf20a
3 N8e22f2b737924951887aacaf668b88af
4 Nc8b48c2644ff4776b3ac4fbbb1a49731
5 anzsrc-for:11
6 anzsrc-for:1112
7 schema:author N2179df03bd8a4a38a7f10fa2c4060be0
8 schema:citation sg:pub.10.1007/s11912-009-0054-y
9 sg:pub.10.1038/459336a
10 sg:pub.10.1038/nature00766
11 sg:pub.10.1038/nature03890
12 sg:pub.10.1038/nature07586
13 sg:pub.10.1038/ng1054
14 sg:pub.10.1038/onc.2008.362
15 sg:pub.10.1038/sj.bjc.6603291
16 sg:pub.10.1038/sj.onc.1206461
17 sg:pub.10.2165/00003495-200767080-00003
18 schema:datePublished 2010-03-24
19 schema:datePublishedReg 2010-03-24
20 schema:description Immunotherapy and chemotherapy benefit few patients with metastatic melanoma, and even fewer experience durable survival benefit. These poor results come from treating melanoma as a single homogeneous disease. Recently, it has been shown that targeting activated tyrosine kinases (oncogenes) can mediate striking clinical benefits in several cancers. In 2002, a mutation at the V600E amino acid of the BRAF serine/threonine kinase was described as present in over 50% of melanomas. The mutation appeared to confer a dependency by the melanoma cancer cell on its activation of the MAP kinase pathway. The frequency and specificity of this mutation (95% at V600E of BRAF) suggests that it may be a potential target for therapy, and recent results with one inhibitor, PLX4032/RG7204, bare this out. This review updates the status of BRAF inhibitors in melanoma and what may be on the horizon.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf Na34edecdd0bf41bc972fd4d205359d8d
24 Nbffb07abd57d465a95a22786f1a5828f
25 sg:journal.1021174
26 schema:keywords BRAF inhibitors
27 BRAF serine/threonine kinase
28 MAP kinase pathway
29 acid
30 activation
31 amino acids
32 benefits
33 cancer
34 cancer cells
35 cells
36 chemotherapy
37 clinical benefit
38 dependency
39 disease
40 durable survival benefit
41 evolving role
42 frequency
43 homogeneous disease
44 horizon
45 immunotherapy
46 inhibitors
47 kinase
48 kinase pathway
49 malignant melanoma
50 melanoma
51 melanoma cancer cells
52 metastatic melanoma
53 mutations
54 pathway
55 patients
56 poor results
57 potential target
58 recent results
59 results
60 review
61 role
62 serine/threonine kinase
63 specificity
64 status
65 survival benefit
66 target
67 therapy
68 threonine kinase
69 tyrosine kinase
70 schema:name B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma
71 schema:pagination 146-152
72 schema:productId N7c088c9033454a4c87823cf220e3d90e
73 Nb4c92c6e1bc54f2c93e994315acc4389
74 Nd29d0a3aede7496495a0f95272333628
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003251632
76 https://doi.org/10.1007/s11912-010-0095-2
77 schema:sdDatePublished 2022-08-04T16:57
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher N780db095f37a4cf98ebd5b81d3398fe7
80 schema:url https://doi.org/10.1007/s11912-010-0095-2
81 sgo:license sg:explorer/license/
82 sgo:sdDataset articles
83 rdf:type schema:ScholarlyArticle
84 N031f30d448534bedabc989bf1ac923c4 rdf:first sg:person.0640153517.24
85 rdf:rest Nd1c295b4c2c44ca69e70e24d4ce70283
86 N2179df03bd8a4a38a7f10fa2c4060be0 rdf:first Nba6141376f4c4122b24adb1eb8d5f49c
87 rdf:rest N031f30d448534bedabc989bf1ac923c4
88 N52d8eb9040b3474bbefaa127a7468c0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Proto-Oncogene Proteins B-raf
90 rdf:type schema:DefinedTerm
91 N780db095f37a4cf98ebd5b81d3398fe7 schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 N7c088c9033454a4c87823cf220e3d90e schema:name dimensions_id
94 schema:value pub.1003251632
95 rdf:type schema:PropertyValue
96 N7d5febe9d4534938ac6118b1f50cf20a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Antineoplastic Agents
98 rdf:type schema:DefinedTerm
99 N8e22f2b737924951887aacaf668b88af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Melanoma
101 rdf:type schema:DefinedTerm
102 Na34edecdd0bf41bc972fd4d205359d8d schema:issueNumber 3
103 rdf:type schema:PublicationIssue
104 Nb4c92c6e1bc54f2c93e994315acc4389 schema:name pubmed_id
105 schema:value 20425073
106 rdf:type schema:PropertyValue
107 Nba6141376f4c4122b24adb1eb8d5f49c schema:affiliation grid-institutes:grid.412807.8
108 schema:familyName Shepherd
109 schema:givenName Cynthia
110 rdf:type schema:Person
111 Nbffb07abd57d465a95a22786f1a5828f schema:volumeNumber 12
112 rdf:type schema:PublicationVolume
113 Nc8b48c2644ff4776b3ac4fbbb1a49731 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Humans
115 rdf:type schema:DefinedTerm
116 Nd1c295b4c2c44ca69e70e24d4ce70283 rdf:first sg:person.07375610737.64
117 rdf:rest rdf:nil
118 Nd29d0a3aede7496495a0f95272333628 schema:name doi
119 schema:value 10.1007/s11912-010-0095-2
120 rdf:type schema:PropertyValue
121 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
122 schema:name Medical and Health Sciences
123 rdf:type schema:DefinedTerm
124 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
125 schema:name Oncology and Carcinogenesis
126 rdf:type schema:DefinedTerm
127 sg:grant.2420926 http://pending.schema.org/fundedItem sg:pub.10.1007/s11912-010-0095-2
128 rdf:type schema:MonetaryGrant
129 sg:journal.1021174 schema:issn 1523-3790
130 1534-6269
131 schema:name Current Oncology Reports
132 schema:publisher Springer Nature
133 rdf:type schema:Periodical
134 sg:person.0640153517.24 schema:affiliation grid-institutes:grid.412807.8
135 schema:familyName Puzanov
136 schema:givenName Igor
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24
138 rdf:type schema:Person
139 sg:person.07375610737.64 schema:affiliation grid-institutes:grid.412807.8
140 schema:familyName Sosman
141 schema:givenName Jeffrey A.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07375610737.64
143 rdf:type schema:Person
144 sg:pub.10.1007/s11912-009-0054-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1005461340
145 https://doi.org/10.1007/s11912-009-0054-y
146 rdf:type schema:CreativeWork
147 sg:pub.10.1038/459336a schema:sameAs https://app.dimensions.ai/details/publication/pub.1015003021
148 https://doi.org/10.1038/459336a
149 rdf:type schema:CreativeWork
150 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
151 https://doi.org/10.1038/nature00766
152 rdf:type schema:CreativeWork
153 sg:pub.10.1038/nature03890 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003324113
154 https://doi.org/10.1038/nature03890
155 rdf:type schema:CreativeWork
156 sg:pub.10.1038/nature07586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018711414
157 https://doi.org/10.1038/nature07586
158 rdf:type schema:CreativeWork
159 sg:pub.10.1038/ng1054 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035969538
160 https://doi.org/10.1038/ng1054
161 rdf:type schema:CreativeWork
162 sg:pub.10.1038/onc.2008.362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024888641
163 https://doi.org/10.1038/onc.2008.362
164 rdf:type schema:CreativeWork
165 sg:pub.10.1038/sj.bjc.6603291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005853584
166 https://doi.org/10.1038/sj.bjc.6603291
167 rdf:type schema:CreativeWork
168 sg:pub.10.1038/sj.onc.1206461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049450168
169 https://doi.org/10.1038/sj.onc.1206461
170 rdf:type schema:CreativeWork
171 sg:pub.10.2165/00003495-200767080-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012080940
172 https://doi.org/10.2165/00003495-200767080-00003
173 rdf:type schema:CreativeWork
174 grid-institutes:grid.412807.8 schema:alternateName Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA
175 schema:name Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA
176 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...